Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 9Prostatic Neoplasms 6Neoplasms 6Multiple Myeloma 4Fractures, Bone 4Osteoporosis 3Bone Diseases, Metabolic 3Spinal Cord Compression 2Giant Cell Tumor of Bone 2Bone Metastases 2Bone Diseases 2Parathyroid Neoplasms 1Paraproteinemias 1Neoplastic Processes 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Mastocytosis, Systemic 1Lymphoma 1Hyperparathyroidism, Primary 1Hormone Refractory Prostate Cancer 1Hematologic Neoplasms 1Hematologic Diseases 1Cataract 1Castrate-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Diseases 1Bone Neoplasms 1

Interventions

Carboplatin 17Cisplatin 14Paclitaxel 12Pemetrexed 11pembrolizumab 9Gemcitabine 7Docetaxel 6Sorafenib 5osimertinib 4durvalumab 4130-nm albumin-bound paclitaxel 4padeliporfin 3cabozantinib 3atezolizumab 3Taxes 3Radiotherapy 3Mitomycin 3Magnetic Resonance Spectroscopy 3Cetuximab 3Bevacizumab 31-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3trifluridine tipiracil drug combination 2regorafenib 2olaparib 2Sunitinib 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2Radiation 2Nivolumab 2Irinotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma × Denosumab × Clear all
NCT00838201 2018-10-18

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Amgen

Phase 3 Completed
384 enrolled 8 charts
Genitourinary

Carcinoma, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡